<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Severe acute respiratory syndrome (SARS)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Severe acute respiratory syndrome (SARS)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Severe acute respiratory syndrome (SARS)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth McIntosh, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allyson Bloom, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 07, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In February 2003, the World Health Organization (WHO) reported about 300 cases of a rapidly progressive respiratory illness in the Guangdong Province of China with five deaths. Over the next month, similar cases were reported from Hong Kong, Vietnam, Singapore, and Canada [
         <a href="#rid1">
          1
         </a>
         ]. By the end of the worldwide outbreak in July 2003, a total of 8096 cases were reported, with 774 deaths and a case-fatality rate of 9.6 percent [
         <a href="#rid2">
          2
         </a>
         ]. WHO termed the disease "severe acute respiratory syndrome" (SARS) and the identified case was a novel coronavirus termed SARS coronavirus (SARS-CoV). Once another novel coronavirus emerged in 2019 and was designated SARS-CoV-2, SARS-CoV became known as SARS-CoV-1.
        </p>
        <p>
         No cases of SARS-CoV-1 have been reported since mid-2004. However, re-emergence of SARS and SARS-CoV-1 is theoretically possible, even in the presence of the Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2, the cause of coronavirus disease 2019 (COVID-19).
        </p>
        <p>
         The case definition, epidemiology, etiology, clinical manifestations, diagnosis, treatment, and prevention of SARS will be reviewed here. Coronaviruses, including MERS-CoV and SARS-CoV-2, are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8298.html" rel="external">
          "Coronaviruses"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89705.html" rel="external">
          "Middle East respiratory syndrome coronavirus: Virology, pathogenesis, and epidemiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">
          "COVID-19: Epidemiology, virology, and prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CASE DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         During and in the immediate aftermath of the SARS epidemic, both the World Health Organization (WHO) and the United States Centers for Disease Control and Prevention (CDC) issued case definitions for SARS. The WHO definition was subsequently updated and notes that in the absence of current SARS activity in humans, laboratory confirmation using reliable and experienced laboratories, such as those at the WHO and the CDC, is a critical component of the case definition [
         <a href="#rid3">
          3
         </a>
         ]. The updated WHO definition is outlined here for historical reasons and in the event of a re-emergence.
        </p>
        <p>
         According to the WHO, a case of SARS is notifiable if it occurs in an individual with laboratory confirmation of infection who
         <strong>
          either
         </strong>
         meets the clinical case definition
         <strong>
          or
         </strong>
         has worked in a laboratory with live SARS coronavirus or with clinical specimens infected with SARS coronavirus [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The clinical case definition used by the WHO includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A history of fever or documented fever
         <strong>
          and
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One or more symptoms of lower respiratory tract illness (cough, difficulty breathing, shortness of breath)
         <strong>
          and
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiographic evidence of lung infiltrates consistent with pneumonia or acute respiratory distress syndrome (ARDS) or autopsy findings consistent with the pathology of pneumonia or ARDS without an identifiable cause
         <strong>
          and
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No alternative diagnosis fully explaining the illness
        </p>
        <p>
        </p>
        <p>
         Laboratory diagnostic tests that are required include one or both of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Detection of virus by an assay for viral RNA (reverse-transcriptase polymerase chain reaction) present in two separate samples or by virus culture from any clinical specimen. These two samples can be obtained from either two separate sites (eg, nasopharyngeal and stool) or from the same site but at different times (eg, sequential nasopharyngeal aspirates).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Detection of antibody (a rise in antibody titer, either from negative to positive or at least a fourfold increase) by enzyme-linked immunosorbent assay and/or immunofluorescent assay.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cases of SARS were first noted in Guangdong Province, China, in November 2002. Between November 16, 2002, and February 28, 2003, 792 cases were reported in this province [
         <a href="#rid4">
          4,5
         </a>
         ]. Healthcare workers and their contacts appeared to be disproportionately affected by the outbreak.
        </p>
        <p>
         The index case for the illness in Hong Kong was a physician from Guangdong Province who traveled to Hong Kong five days after the onset of symptoms [
         <a href="#rid6">
          6
         </a>
         ]. Other cases in Hong Kong developed in those with contact with the index or secondary cases, including individuals staying at the same hotel as the index patient. The index cases in Singapore, Thailand, Vietnam, and Canada were in travelers returning from Guangdong Province or Hong Kong.
        </p>
        <p>
         The illness had many epidemiologic and clinical features of an infection, and early efforts to find an associated pathogen quickly centered around a new viral strain from the coronavirus family, first identified in February and March 2003 [
         <a href="#rid7">
          7-9
         </a>
         ]. The virus spread rapidly from southern China and Hong Kong to Vietnam, Thailand, and Singapore, and then to Europe, Canada, and the United States.
        </p>
        <p>
         Local epidemics in Hong Kong, Singapore, Toronto, and parts of China through March led the World Health Organization (WHO) and the United States Centers for Disease Control and Prevention (CDC) to issue several travel advisories on or around April 1, 2003. These were combined with extraordinary efforts at containment through application of infection-control practices, particularly in hospitals. By July 2003, no new cases were reported worldwide and the WHO lifted its last remaining travel advisory.
        </p>
        <p>
         During the remainder of 2003 and the first half of 2004, four small outbreaks of SARS were documented following the apparent end of the epidemic. Three outbreaks were related to laboratory transmission of the epidemic virus, and one was presumably from contact with animal sources. Since mid-2004, no cases have been reported. (See
         <a class="local">
          'Intermediate host and reservoir'
         </a>
         below.)
        </p>
        <p>
         Most illnesses occurred in adults [
         <a href="#rid10">
          10
         </a>
         ]. Children 12 years or older had a clinical presentation similar to adults, whereas younger children had milder disease [
         <a href="#rid11">
          11,12
         </a>
         ]. No fatal cases were reported among children.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Scope of outbreak
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 2002 to 2003 outbreak resulted in 8096 cases with 774 deaths and a case-fatality rate of 9.6 percent [
         <a href="#rid2">
          2
         </a>
         ]. Older age was associated with a higher mortality rate, being as high as 43 percent in patients age 60 or older in Hong Kong compared with 13 percent in younger patients [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Cases of SARS occurred in 29 countries in Asia, Europe, and North America. China, including Hong Kong, had 83 percent of all cases. The United States had 27 probable cases with no secondary cases and no deaths. In Canada, mainly in Toronto, there were 251 cases (5 imported and the rest secondary) with 43 deaths [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The small outbreaks that followed the major SARS epidemic are of considerable interest as models of possible future SARS outbreaks [
         <a href="#rid14">
          14
         </a>
         ]. Two outbreaks that presumably originated in laboratories working with the SARS coronavirus involved only a single case with no secondary spread [
         <a href="#rid14">
          14,15
         </a>
         ]. In a third laboratory-based outbreak that occurred in China in April 2004, there were nine cases in three generations of contacts and one death [
         <a href="#rid16">
          16
         </a>
         ]. A fourth outbreak, in December 2003 and January 2004, consisted of four relatively mild and epidemiologically separate cases, all in Guangdong Province in southern China, and all presumably from contact with infected animals, probably palm civets [
         <a href="#rid14">
          14,17,18
         </a>
         ].
        </p>
        <p>
         These small outbreaks illustrate several important principles:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There must be strict control of laboratory strains.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory strains, presumably because they represent strains that have been adapted to spread among humans, can cause outbreaks; in contrast, animal-derived strains are less likely to cause outbreaks without some period of adaptation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Control of possible animal intermediaries is important in preventing reemergence of SARS. Since 2004, China has banned all consumption of palm civets [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Intermediate host and reservoir
         </span>
         <span class="headingEndMark">
          —
         </span>
         Animals eaten as exotic foods in southern China were probably intermediate hosts. The Chinese government launched an effort to kill palm civets, a cat-like creature considered a culinary delicacy in China that was sometimes infected by a coronavirus similar to the SARS coronavirus. A direct link between civets and SARS has not been confirmed, although molecular studies have suggested that SARS coronaviruses isolated early in the epidemic were closely related to palm civet coronaviruses [
         <a href="#rid20">
          20-22
         </a>
         ].
        </p>
        <p>
         Two studies demonstrated infection of a relatively high percentage of horseshoe bats (genus
         <em>
          Rhinolophus
         </em>
         ) in China with viruses that have nucleotide sequences closely related to SARS [
         <a href="#rid23">
          23,24
         </a>
         ]. In a later study, the genomes of two novel bat coronaviruses from horseshoe bats in China were sequenced and found to resemble SARS coronavirus more than any previously identified bat coronavirus [
         <a href="#rid25">
          25
         </a>
         ]. In addition, two replicating bat coronaviruses, SARS-like coronaviruses WIV1 [
         <a href="#rid25">
          25
         </a>
         ] and WIV16 [
         <a href="#rid26">
          26
         </a>
         ], were isolated from
         <em>
          Rhinolophus sinica
         </em>
         feces in tissue culture. Both viruses use angiotensin-converting enzyme 2 (ACE2) from humans, civets, and Chinese horseshoe bats for cell entry; ACE2 is a functional receptor for SARS coronavirus. Studies of the sequences and functions of the receptor-binding region of the S gene, the open reading frame 3A, and the hypervariable open reading frame 8 have added further evidence of a close genetic relationship between certain
         <em>
          Rhinolophus
         </em>
         bat coronaviruses (particularly bats found through intensive study of a cave in Yunnan province of China) and the virus that caused the SARS epidemic [
         <a href="#rid27">
          27,28
         </a>
         ]. These findings suggest that bats are likely to be an important reservoir for this virus. Moreover, coronaviruses resembling the SARS coronavirus, as well as others closely related to the Middle East respiratory syndrome coronavirus, have been found in bats on several continents outside Asia [
         <a href="#rid29">
          29-32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/89705.html" rel="external">
          "Middle East respiratory syndrome coronavirus: Virology, pathogenesis, and epidemiology", section on 'Bats'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Transmission
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon the clusters of cases in Hong Kong and Canada, SARS coronavirus clearly spread from person to person and could be acquired from face-to-face contact, suggesting droplet spread [
         <a href="#rid6">
          6,33-35
         </a>
         ]. Because of the rapid and extensive spread of SARS in Hong Kong, there has also been speculation that other dissemination modes, such as fecal-oral or airborne spread, might occur. Airborne spread is the most likely explanation for "superspreader" events, including the small outbreak that occurred on an aircraft [
         <a href="#rid36">
          36
         </a>
         ] and, possibly, the large, explosive outbreak in Amoy Gardens and surrounding residential building complexes in Hong Kong [
         <a href="#rid37">
          37,38
         </a>
         ]. Superspreaders are individuals who are responsible for a disproportionately large number of transmission events [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Transmission to healthcare workers has been a common feature of most SARS outbreaks. A possible contributing factor is that peak viral shedding in respiratory secretions, as determined by polymerase chain reaction (PCR), occurs 6 to 11 days following the onset of illness, at a time of severe respiratory symptoms [
         <a href="#rid40">
          40,41
         </a>
         ]. This late viral excretion peak is unusual for a respiratory virus.
        </p>
        <p>
         Fomites are another possible contributor to nosocomial transmission. SARS virus RNA is present in stool and was detected on a variety of hospital surfaces (eg, hospital bed tables, television remote controls, refrigerator doors) during outbreaks [
         <a href="#rid33">
          33,42
         </a>
         ]. Fomites have also been implicated in an analysis of an outbreak of SARS aboard an airplane [
         <a href="#rid43">
          43
         </a>
         ]. This emphasizes the need for strict surface hygiene practices.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Molecular epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is likely that, after one or more instances of spread from animals to humans, the SARS coronavirus adapted through mutation, deletions, and possibly recombination, until it transmitted readily among humans. The virus that spread worldwide was derived primarily from a single infected individual who traveled from Guangdong Province to Hong Kong and infected numerous individuals in a superspreading event [
         <a href="#rid44">
          44
         </a>
         ]. The virus that was epidemic in China and produced the majority of probable infections was more variable [
         <a href="#rid19">
          19,45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Incubation period
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incubation period for SARS is usually two to seven days [
         <a href="#rid13">
          13
         </a>
         ]. Approximately 95 percent of patients will develop symptoms within 10 days [
         <a href="#rid13">
          13
         </a>
         ]. Thus, after possible exposure, an individual should be monitored for the development of symptoms for at least 10 days. There is also an apparent association between more severe clinical manifestations and a shorter incubation period [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Prognostic features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidemiologic studies have identified a number of risk factors for poor outcomes in patients with SARS. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older age [
         <a href="#rid10">
          10,13,41
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes, chronic hepatitis B, and other underlying comorbid conditions [
         <a href="#rid10">
          10,41,47
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atypical presenting symptoms [
         <a href="#rid10">
          10
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated serum lactate dehydrogenase on admission [
         <a href="#rid10">
          10,48
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Relatively few infections and no deaths were reported in children or adolescents in a survey from Hong Kong [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early in the course of the investigations, it was suspected that SARS was a viral respiratory illness. A novel coronavirus was detected in specimens from a number of patients with SARS, and the virus was sequenced and fulfilled Koch's postulates, including causing severe respiratory disease in inoculated cynomolgus macaques [
         <a href="#rid49">
          49-52
         </a>
         ]. Coronaviruses are usually agents of the common cold and generally do not cause severe respiratory disease. (See
         <a class="medical medical_review" href="/z/d/html/8298.html" rel="external">
          "Coronaviruses"
         </a>
         .)
        </p>
        <p>
         Investigators at the United States Centers for Disease Control and Prevention identified a novel coronavirus in cell cultures inoculated with specimens from two patients in Thailand and Hong Kong [
         <a href="#rid8">
          8
         </a>
         ]. At the same time, coronaviruses were isolated from index cases in Germany and Hong Kong [
         <a href="#rid7">
          7,9
         </a>
         ]. Preliminary sequence analysis suggested that the viruses were similar and represented a previously undescribed coronavirus.
        </p>
        <p>
         The SARS coronavirus genome has an organization similar to that of other coronaviruses [
         <a href="#rid50">
          50
         </a>
         ]. It has been classified as a lineage B beta-coronavirus (with several bat coronaviruses) [
         <a href="#rid53">
          53
         </a>
         ]. Through a variety of clinical, animal, and laboratory studies, the etiologic association between the SARS coronavirus and SARS has been clearly established [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Knowledge of the pathogenesis and immune responses to SARS coronavirus is limited. Autopsy studies of patients who died during the first 10 days of illness confirm that the lung is an early target [
         <a href="#rid54">
          54
         </a>
         ]. Virus was consistently found in the lung and intestinal tract [
         <a href="#rid8">
          8,9
         </a>
         ]. In fatal cases, virus was found in multiple organs, including the brain.
        </p>
        <p>
         The adaptive immune system is probably critical to recovery from SARS, as demonstrated in experiments in mouse models [
         <a href="#rid55">
          55
         </a>
         ]. It is also likely that the innate immune system, including the complement system [
         <a href="#rid56">
          56
         </a>
         ], plays a role, both in defense against and in the pathogenesis of SARS. Genetic studies have pointed to the interleukin 12 receptor and the mannose-binding lectin as potential important first lines of defense [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p>
         Angiotensin-converting enzyme 2 (ACE2) and CD209L (L-SIGN) are functional receptors for SARS [
         <a href="#rid59">
          59,60
         </a>
         ]. In an animal model, infection of ACE2 knockout mice led to recovery of low quantities of infectious virus compared with large amounts in the wild-type mice [
         <a href="#rid61">
          61
         </a>
         ]. The authors of this report hypothesized that infection with SARS results in downregulation of ACE2 and subsequent lung pathology, since ACE2 has a key protective role in acute lung injury. Several cellular proteolytic enzyme systems also facilitate entry of virus into the cell [
         <a href="#rid62">
          62,63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Signs and symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         SARS is an unusual respiratory viral disease since the prodrome is often somewhat prolonged, lasting for three to seven days, and is characterized by fever (temperature ≥100.5ºF [&gt;38ºC]) malaise, headache, and myalgias [
         <a href="#rid64">
          64
         </a>
         ]. Unlike virtually all other respiratory viral prodromes, most patients have no upper respiratory symptoms during this stage. At the end of this prodrome, the respiratory phase typically begins with a nonproductive cough. Dyspnea may follow and may progress to respiratory failure, with progressive pulmonary infiltrates on chest radiograph, necessitating mechanical ventilation.
        </p>
        <p>
         A comprehensive review of the clinical manifestations associated with SARS summarizes data from 752 patients from mainland China (190 cases), Hong Kong (388 cases), Canada (154 cases), and Singapore (20 cases) [
         <a href="#rid5">
          5
         </a>
         ]. The most common symptoms and signs on presentation to hospital were:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever – 100 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cough – 66 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chills and/or rigors – 52 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myalgias – 49 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dyspnea – 46 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Headache – 39 percent
        </p>
        <p>
        </p>
        <p>
         Other less common symptoms were diarrhea (20 percent) and chest pain or pleurisy (22 percent). Sore throat and rhinorrhea were seen in 17 and 14 percent, respectively. Symptoms observed in 346 laboratory-proven cases in Taiwan were similar [
         <a href="#rid65">
          65
         </a>
         ]. All respiratory symptoms (cough, dyspnea, pleuritic pain) became more common and severe as the disease progressed. Approximately 25 percent of patients required transfer to the intensive care unit (ICU), usually for mechanical ventilation [
         <a href="#rid6">
          6,41,47,66-68
         </a>
         ]. Death was usually caused by a combination of adult respiratory distress syndrome and multiorgan failure.
        </p>
        <p>
         Asymptomatic infection during the large SARS epidemic was infrequent, although animal handlers in southern China were found to have a high rate of antibody with no history of typical illness [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common laboratory abnormalities were depressed total lymphocytes (66 percent) and elevated lactate dehydrogenase (LDH; 46 percent) and alanine aminotransferase (44 percent) [
         <a href="#rid5">
          5
         </a>
         ]. Thrombocytopenia was present in 30 percent, usually as the respiratory phase peaked. High LDH was associated with a poor outcome [
         <a href="#rid10">
          10,48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest radiograph patterns ranged from normal to diffuse interstitial infiltrates characteristic of acute respiratory distress syndrome [
         <a href="#rid69">
          69,70
         </a>
         ]. Bilateral peripheral infiltrates were common, usually in the middle or lower lung zones (
         <a class="graphic graphic_diagnosticimage graphicRef62522" href="/z/d/graphic/62522.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         Computed tomographic (CT) scanning can show parenchymal abnormalities in patients with apparently normal chest radiographs (
         <a class="graphic graphic_diagnosticimage graphicRef75323" href="/z/d/graphic/75323.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid72">
          72
         </a>
         ]. Infiltrates are usually ground glass in character and peripheral in location.
        </p>
        <p>
         Long-term follow-up pulmonary CT studies in SARS survivors demonstrate persistent abnormalities seven years after infection, with reticulation and interlobular thickening replacing ground-glass opacities in most subjects and mild to moderate changes in pulmonary function tests [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Information about the effect of SARS on pregnant women and their fetuses is limited. Two reports from the same group at a hospital in Hong Kong suggested that pregnant women with SARS had a higher mortality rate and higher rates of both intubation and ICU admission than nonpregnant women with SARS but that transmission of the virus to the infant did not occur [
         <a href="#rid74">
          74,75
         </a>
         ]. Complications, such as miscarriages, preterm deliveries, and small for gestational age neonates, were frequent.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          PATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse alveolar damage with varying degrees of organization is seen on pathologic examination in patients with SARS who have acute lung injury [
         <a href="#rid54">
          54,76
         </a>
         ]. Severe disease with lung injury is believed to reflect an excessive host response with production of large quantities of proinflammatory cytokines ("cytokine storm") [
         <a href="#rid77">
          77
         </a>
         ]. Histologic features vary with the stage of disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the early phase, hyaline membranes, interstitial and intraalveolar edema, and vascular congestion are present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the organizing phase, fibroblast proliferation occurs both in the interstitium and alveolar spaces.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the organizing phase, the majority of fibroblast proliferation occurs within alveolar septa.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         During the 2002 to 2003 epidemic, the United States Centers for Disease Control and Prevention supplied reagents to laboratories in the United States to test for serum coronavirus antibodies from paired acute and convalescent samples from suspected cases. Because of justified concerns about false-positive diagnostic tests, the World Health Organization (WHO) requires that positive laboratory tests from suspected cases be repeated and confirmed in central WHO laboratories.
        </p>
        <p>
         When SARS is suspected, specimens for polymerase chain reaction (PCR) testing should be obtained from at least two sites, such as the respiratory tract, stool, and serum or plasma. PCR testing should be performed as early in the illness as possible and, if symptoms progress or persist, be repeated five to seven days later. Acute and convalescent serum should also be collected for serologic testing. The results required to establish the diagnosis of SARS are discussed above. (See
         <a class="local">
          'Case definitions'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Serologic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum antibody, usually measured by enzyme-linked immunosorbent assay, is the most sensitive of available tests. However, antibodies typically develop several weeks into the illness, making serologic testing less useful for diagnosis during the acute phase. As an example, the mean time to seroconversion was 19 and 20 days in two series [
         <a href="#rid41">
          41,78
         </a>
         ], and a small number of patients failed to develop antibody even later in the illness.
        </p>
        <p>
         Due to the antigenic similarity among coronaviruses, antibodies to SARS coronavirus sometimes develop after other respiratory coronavirus infections [
         <a href="#rid79">
          79,80
         </a>
         ]. Thus, serologic testing for SARS may give false-positive results.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Polymerase chain reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reverse-transcriptase PCR (RT-PCR), including quantitative real-time RT-PCR, was performed on respiratory, stool, and serum or plasma samples in many patients with SARS, but no systematic study has been performed to determine the relative value of each type of specimen at various stages of illness.
        </p>
        <p>
         The following findings have been observed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RT-PCR assays performed on samples obtained early in the illness had sensitivities as low as 50 percent [
         <a href="#rid81">
          81,82
         </a>
         ]. Optimization using real-time PCR increased the sensitivity in some studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The sensitivity of serum or plasma appears to be greatest early in the illness (between one and seven days after onset of fever) and diminishes markedly with time [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasopharyngeal aspirates may, if all conditions are optimized, be sensitive at the time of admission to the hospital [
         <a href="#rid84">
          84
         </a>
         ] but appear to be most sensitive at the time of peak respiratory symptoms, usually during the second week of illness [
         <a href="#rid41">
          41,82
         </a>
         ]. In one study that included 75 patients, 32 percent had a positive RT-PCR assay three days following the onset of illness compared with 68 percent at day 14 [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stool samples remain PCR positive for the longest period, with 65 of 67 samples (97 percent) in one report being positive a mean of 14 days after illness onset [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Both serum and respiratory virus titers as measured by real-time RT-PCR have been correlated with prognosis, with higher titers associated with worse prognosis [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         No specific treatment is recommended except for meticulous supportive care [
         <a href="#rid86">
          86
         </a>
         ]. As with other viral infections, antibacterial agents are ineffective. In addition, no antiviral agents have been found to provide benefit for treating SARS. During the epidemic, most patients were treated with high-dose glucocorticoids and
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         , but most experts now agree that neither treatment had a clear beneficial effect, and immediate and late toxicities were common [
         <a href="#rid87">
          87,88
         </a>
         ].
         <a class="drug drug_general" data-topicid="9982" href="/z/d/drug information/9982.html" rel="external">
          Lopinavir-ritonavir
         </a>
         may have some activity against the virus in vitro, but its clinical efficacy has not been established [
         <a href="#rid89">
          89
         </a>
         ].
         <a class="drug drug_general" data-topicid="127259" href="/z/d/drug information/127259.html" rel="external">
          Remdesivir
         </a>
         (GS-5734), has in vitro activity against the SARS and MERS coronaviruses [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stringent infection-control practices are crucial for the prevention of SARS, since other modalities such as a vaccine and monoclonal antibodies remain in development.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Infection control
         </span>
         <span class="headingEndMark">
          —
         </span>
         The control of SARS through the rigorous application of barrier methods represents one of the landmark accomplishments of infectious diseases epidemiology and public health coordination. One of the characteristics of the infection, namely the low contagiousness of patients during the prodrome, probably contributed to the success of control efforts, since patients could, in the outbreak situation, be identified and placed on precautions before they became most infectious to contacts. But the disappearance of SARS in July 2003, only nine months after it had first been detected, was a substantial international public health accomplishment. Isolation of patients, rigorous use of masks, gloves, and gowns, closure of schools, hospitals, and clubs, and quarantine of exposed individuals probably all contributed to containment of the outbreak [
         <a href="#rid91">
          91-93
         </a>
         ].
        </p>
        <p>
         Both surgical masks and N95 respirators were demonstrated to be useful in blocking the spread of SARS, with no added advantage to N95 respirators over masks [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Vaccine development
         </span>
         <span class="headingEndMark">
          —
         </span>
         Efforts are underway to prepare a vaccine for the prevention of SARS, and a large number of candidate vaccines have been developed [
         <a href="#rid95">
          95
         </a>
         ]. Most efforts have concentrated on developing antibody (either secretory or systemic, or both) to the surface S glycoprotein, since neutralizing antibody is directed against the receptor-binding portion of this molecule (
         <a class="graphic graphic_figure graphicRef74041" href="/z/d/graphic/74041.html" rel="external">
          figure 1
         </a>
         ). There is controversy regarding the potential inclusion of the M protein as a component of a vaccine. Although the M protein is an immunodominant protein and may be important as a target of cell-mediated immunity, there is disagreement about its capacity to induce neutralizing antibody and therefore its importance as an antigen in a preventive vaccine [
         <a href="#rid96">
          96-98
         </a>
         ]. There is some concern that, by analogy with some animal coronavirus diseases, immunization might cause paradoxically severe disease on subsequent exposure to natural infection.
        </p>
        <p>
         The following illustrate several approaches that have been evaluated:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A recombinant receptor-binding domain S glycoprotein vaccine produced in fungi, bacteria, or insect or mammalian tissue culture protects mice fully with no evidence of paradoxically severe disease [
         <a href="#rid99">
          99,100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         DNA vaccine approaches have induced antigen-specific antibody and cellular immune responses as well as protection in murine models [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intranasal immunization of monkeys with an attenuated parainfluenza virus that expressed the SARS spike protein resulted in no viral shedding after exposure to the SARS virus [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In contrast, the following are models of vaccines that produced paradoxically severe disease on subsequent exposure to the SARS coronavirus:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mice immunized intradermally with vaccinia virus constructs containing the nucleoprotein gene of the SARS coronavirus developed severe pneumonia following subsequent intranasal exposure to SARS coronavirus itself, in contrast with those immunized with vaccinia virus constructs containing the S protein gene, who were protected [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macaques immunized with modified vaccinia Ankara (MVA) encoding full-length SARS spike protein and then challenged with live SARS virus developed greater histologic evidence of acute lung injury than animals challenged after receiving MVA alone [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Tests of these candidate vaccines have not been carried out in human subjects.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Monoclonal antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Administration of monoclonal antibodies is another potential approach to the prevention of SARS, although none are available for clinical use. Humanized monoclonal antibodies directed at specific portions of the S glycoprotein have been developed singly and in combination to effectively neutralize virus in vitro and prevent infection in animal models, as illustrated by the following examples (
         <a class="graphic graphic_figure graphicRef74041" href="/z/d/graphic/74041.html" rel="external">
          figure 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Human monoclonal antibody to the S1 domain of the spike protein led to potent neutralization of SARS coronavirus in vitro [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several widely conserved amino acids in the receptor-binding domain in the S1 region of the S glycoprotein have been identified that are critical in neutralization of the virus [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A combination of two noncompeting human monoclonal antibodies broadened protection in vitro by reducing immune escape [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In February 2003, the World Health Organization (WHO) reported about 300 cases of a rapidly progressive respiratory illness in the Guangdong Province of China with five deaths. Over the next month, similar cases were reported from Hong Kong, Vietnam, Singapore, and Canada. The illness was termed severe acute respiratory syndrome (SARS) and was found to be caused by a novel coronavirus, designated SARS coronavirus (SARS-CoV) and later called SARS-CoV-1. The outbreak resulted in a total of 8096 cases with 774 deaths and a case-fatality rate of 9 to 12 percent. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Since mid-2004, no cases of SARS-CoV-1 have been reported. The information presented here is mainly of historical interest, although re-emergence of SARS and SARS-CoV-1 is theoretically possible. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If SARS is suspected, specimens for polymerase chain reaction (PCR) testing should be obtained from at least two sites, such as the respiratory tract, stool, and serum or plasma. PCR testing should be performed as early in the illness as possible and, if symptoms progress or persist, be repeated five to seven days later. Acute and convalescent serum should also be collected for serologic testing. The results required to establish the diagnosis of SARS are discussed above. (See
         <a class="local">
          'Case definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Animals eaten as exotic foods in southern China, particularly the palm civet, may have been intermediate hosts. Some data have raised the possibility that bats are likely to have been a reservoir for this virus. (See
         <a class="local">
          'Intermediate host and reservoir'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Based upon the clusters of cases in Hong Kong and Canada, SARS coronavirus clearly spread from person to person and could have been acquired from face-to-face contact, suggesting droplet spread. Other modes of spread, such as fecal-oral, airborne, and fomites might also have been possible. (See
         <a class="local">
          'Transmission'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SARS begins with a prodrome lasting for three to seven days characterized by fever, malaise, headache, and myalgias. At the end of this prodrome, the respiratory phase typically begins with a nonproductive cough. Dyspnea may follow and may progress to respiratory failure. (See
         <a class="local">
          'Signs and symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse alveolar damage with varying degrees of organization was seen on pathologic examination in patients with SARS who had acute lung injury. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of SARS consisted of meticulous supportive care, including mechanical ventilation when indicated. Neither antivirals nor glucocorticoids had demonstrated efficacy for SARS. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Meticulous infection-control practices were crucial for the prevention of SARS, since other modalities such as a vaccine and monoclonal antibodies were not available. (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Outbreak of severe acute respiratory syndrome--worldwide, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:226.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 (based on data as of the 31 December 2003). http://www.who.int/csr/sars/country/table2004_04_21/en/index.html (Accessed on December 01, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Case definitions for the 4 diseases requiring notification to WHO in all circumstances under the IHR (2005). Wkly Epidemiol Rec 2009; 84:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christian MD, Poutanen SM, Loutfy MR, et al. Severe acute respiratory syndrome. Clin Infect Dis 2004; 38:1420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. N Engl J Med 2003; 349:2431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348:1967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348:1953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung GM, Hedley AJ, Ho LM, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med 2004; 141:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hon KL, Leung CW, Cheng WT, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 2003; 361:1701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockman LJ, Massoudi MS, Helfand R, et al. Severe acute respiratory syndrome in children. Pediatr Infect Dis J 2007; 26:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donnelly CA, Ghani AC, Leung GM, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003; 361:1761.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Global Alert and Response (GAR): Severe Acute Respiratory Syndrome (SARS). http://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/ (Accessed on December 01, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim PL, Kurup A, Gopalakrishna G, et al. Laboratory-acquired severe acute respiratory syndrome. N Engl J Med 2004; 350:1740.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. China confirms SARS infection in another previously reported case; summary of cases to date – Update 5, 30 April 2004. http://www.who.int/csr/don/2004_04_30/en/ (Accessed on April 02, 2010).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang G, Chen Q, Xu J, et al. Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg Infect Dis 2004; 10:1774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang M, Yan M, Xu H, et al. SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis 2005; 11:1860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao GP. SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era. Philos Trans R Soc Lond B Biol Sci 2007; 362:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 2004; 303:1666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He Y, Li J, Li W, et al. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol 2006; 176:6085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tu C, Crameri G, Kong X, et al. Antibodies to SARS coronavirus in civets. Emerg Infect Dis 2004; 10:2244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 2005; 102:14040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li W, Shi Z, Yu M, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005; 310:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013; 503:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang XL, Hu B, Wang B, et al. Isolation and Characterization of a Novel Bat Coronavirus Closely Related to the Direct Progenitor of Severe Acute Respiratory Syndrome Coronavirus. J Virol 2015; 90:3253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu Z, Yang L, Ren X, et al. ORF8-Related Genetic Evidence for Chinese Horseshoe Bats as the Source of Human Severe Acute Respiratory Syndrome Coronavirus. J Infect Dis 2016; 213:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu B, Zeng LP, Yang XL, et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog 2017; 13:e1006698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drexler JF, Gloza-Rausch F, Glende J, et al. Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol 2010; 84:11336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quan PL, Firth C, Street C, et al. Identification of a severe acute respiratory syndrome coronavirus-like virus in a leaf-nosed bat in Nigeria. MBio 2010; 1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nziza J, Goldstein T, Cranfield M, et al. Coronaviruses Detected in Bats in Close Contact with Humans in Rwanda. Ecohealth 2020; 17:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lecis R, Mucedda M, Pidinchedda E, et al. Molecular identification of Betacoronavirus in bats from Sardinia (Italy): first detection and phylogeny. Virus Genes 2019; 55:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Booth TF, Kournikakis B, Bastien N, et al. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis 2005; 191:1472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donnelly CA, Fisher MC, Fraser C, et al. Epidemiological and genetic analysis of severe acute respiratory syndrome. Lancet Infect Dis 2004; 4:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348:1995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen SJ, Chang HL, Cheung TY, et al. Transmission of the severe acute respiratory syndrome on aircraft. N Engl J Med 2003; 349:2416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu IT, Li Y, Wong TW, et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med 2004; 350:1731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu IT, Qiu H, Tse LA, Wong TW. Severe acute respiratory syndrome beyond Amoy Gardens: completing the incomplete legacy. Clin Infect Dis 2014; 58:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis 2011; 15:e510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng PK, Wong DA, Tong LK, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet 2004; 363:1699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361:1767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiao S, Li Y, Wong TW, Hui DSC. Role of fomites in SARS transmission during the largest hospital outbreak in Hong Kong. PLoS One 2017; 12:e0181558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lei H, Li Y, Xiao S, et al. Routes of transmission of influenza A H1N1, SARS CoV, and norovirus in air cabin: Comparative analyses. Indoor Air 2018; 28:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of individual variation on disease emergence. Nature 2005; 438:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003; 302:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Virlogeux V, Fang VJ, Wu JT, et al. Brief Report: Incubation Period Duration and Severity of Clinical Disease Following Severe Acute Respiratory Syndrome Coronavirus Infection. Epidemiology 2015; 26:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289:2801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi KW, Chau TN, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med 2003; 139:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fouchier RA, Kuiken T, Schutten M, et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 2003; 423:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300:1394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruan YJ, Wei CL, Ee AL, et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003; 361:1779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra MA, Jones SJ, Astell CR, et al. The Genome sequence of the SARS-associated coronavirus. Science 2003; 300:1399.
          </a>
         </li>
         <li class="breakAll">
          de Groot RJ, Ziebuhr J, Poon LL, et al. Revision of the family Coronaviridae, in virus taxonomy: Ninth report of the International Committee on Taxonomy of Viruses. http://www.ictvonline.org/proposals/2008.085-122V.v4.Coronaviridae.pdf (Accessed on October 15, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol 2003; 200:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol 2010; 84:9318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gralinski LE, Sheahan TP, Morrison TE, et al. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio 2018; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang F, Liu W, Zhang F, et al. IL-12 RB1 genetic variants contribute to human susceptibility to severe acute respiratory syndrome infection among Chinese. PLoS One 2008; 3:e2183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ip WK, Chan KH, Law HK, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis 2005; 191:1697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeffers SA, Tusell SM, Gillim-Ross L, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 2004; 101:15748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shulla A, Heald-Sargent T, Subramanya G, et al. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol 2011; 85:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang IC, Bosch BJ, Li F, et al. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem 2006; 281:3198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Preliminary clinical description of severe acute respiratory syndrome. MMWR Morb Mortal Wkly Rep 2003; 52:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsueh PR, Yang PC. Severe acute respiratory syndrome epidemic in Taiwan, 2003. J Microbiol Immunol Infect 2005; 38:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan JW, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003; 58:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu LY, Lee CC, Green JA, et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003; 9:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitar R, Weiser WJ, Avendaño M, et al. Chest radiographic manifestations of severe acute respiratory syndrome in health care workers: the Toronto experience. AJR Am J Roentgenol 2004; 182:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller NL, Ooi GC, Khong PL, Nicolaou S. Severe acute respiratory syndrome: radiographic and CT findings. AJR Am J Roentgenol 2003; 181:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong KT, Antonio GE, Hui DS, et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 2003; 228:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller NL, Ooi GC, Khong PL, et al. High-resolution CT findings of severe acute respiratory syndrome at presentation and after admission. AJR Am J Roentgenol 2004; 182:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu X, Dong D, Ma D. Thin-Section Computed Tomography Manifestations During Convalescence and Long-Term Follow-Up of Patients with Severe Acute Respiratory Syndrome (SARS). Med Sci Monit 2016; 22:2793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 2004; 191:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam CM, Wong SF, Leung TN, et al. A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome. BJOG 2004; 111:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003; 361:1773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 39:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen X, Zhou B, Li M, et al. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis 2004; 189:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan KH, Cheng VC, Woo PC, et al. Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63. Clin Diagn Lab Immunol 2005; 12:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patrick DM, Petric M, Skowronski DM, et al. An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus. Can J Infect Dis Med Microbiol 2006; 17:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang P, Louie M, Richardson SE, et al. Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. CMAJ 2004; 170:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon LL, Guan Y, Nicholls JM, et al. The aetiology, origins, and diagnosis of severe acute respiratory syndrome. Lancet Infect Dis 2004; 4:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng EK, Hui DS, Chan KC, et al. Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem 2003; 49:1976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon LL, Chan KH, Wong OK, et al. Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol 2003; 28:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis 2004; 10:1550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006; 3:e343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiou HE, Liu CL, Buttrey MJ, et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest 2005; 128:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lv H, de Vlas SJ, Liu W, et al. Avascular osteonecrosis after treatment of SARS: a 3-year longitudinal study. Trop Med Int Health 2009; 14 Suppl 1:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groneberg DA, Poutanen SM, Low DE, et al. Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis 2005; 5:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pang X, Zhu Z, Xu F, et al. Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing, 2003. JAMA 2003; 290:3215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svoboda T, Henry B, Shulman L, et al. Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto. N Engl J Med 2004; 350:2352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farquharson C, Baguley K. Responding to the Severe Acute Respiratory Syndrome (SARS) Outbreak: Lessons Learned in a Toronto Emergency Department. J Emerg Nurs 2020; 46:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Offeddu V, Yung CF, Low MSF, Tam CC. Effectiveness of Masks and Respirators Against Respiratory Infections in Healthcare Workers: A Systematic Review and Meta-Analysis. Clin Infect Dis 2017; 65:1934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enjuanes L, Dediego ML, Alvarez E, et al. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res 2008; 133:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Sun Y, Qi J, et al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J Infect Dis 2010; 202:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pang H, Liu Y, Han X, et al. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J Gen Virol 2004; 85:3109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchholz UJ, Bukreyev A, Yang L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A 2004; 101:9804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Du L, Zhao G, Chan CC, et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 2009; 393:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Du L, Zhao G, Chan CC, et al. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol 2010; 23:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang J, Ma R, Wu CY. Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses. Vaccine 2006; 24:4905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bukreyev A, Lamirande EW, Buchholz UJ, et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004; 363:2122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yasui F, Kai C, Kitabatake M, et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 2008; 181:6337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 2019; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 2004; 101:2536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bian C, Zhang X, Cai X, et al. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody. Virology 2009; 383:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ter Meulen J, van den Brink EN, Poon LL, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 2006; 3:e237.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3027 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12665115" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Outbreak of severe acute respiratory syndrome--worldwide, 2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12665115" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Outbreak of severe acute respiratory syndrome--worldwide, 2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19219965" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Case definitions for the 4 diseases requiring notification to WHO in all circumstances under the IHR (2005).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15156481" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14681510" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12671062" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A cluster of cases of severe acute respiratory syndrome in Hong Kong.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12690091" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Identification of a novel coronavirus in patients with severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12690092" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A novel coronavirus associated with severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12711465" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Coronavirus as a possible cause of severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15520422" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12767737" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical presentations and outcome of severe acute respiratory syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17195709" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Severe acute respiratory syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12781533" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12781533" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15103000" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Laboratory-acquired severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15103000" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Laboratory-acquired severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15504263" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16485471" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : SARS-CoV infection in a restaurant from palm civet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17327210" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14752165" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16670317" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15663874" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Antibodies to SARS coronavirus in civets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16169905" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16195424" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Bats are natural reservoirs of SARS-like coronaviruses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24172901" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26719272" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Isolation and Characterization of a Novel Bat Coronavirus Closely Related to the Direct Progenitor of Severe Acute Respiratory Syndrome Coronavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26433221" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : ORF8-Related Genetic Evidence for Chinese Horseshoe Bats as the Source of Human Severe Acute Respiratory Syndrome Coronavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29190287" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20686038" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21063474" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Identification of a severe acute respiratory syndrome coronavirus-like virus in a leaf-nosed bat in Nigeria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31811597" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Coronaviruses Detected in Bats in Close Contact with Humans in Rwanda.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30426315" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Molecular identification of Betacoronavirus in bats from Sardinia (Italy): first detection and phylogeny.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15809906" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15522679" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Epidemiological and genetic analysis of severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12671061" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Identification of severe acute respiratory syndrome in Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14681507" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Transmission of the severe acute respiratory syndrome on aircraft.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15102999" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Evidence of airborne transmission of the severe acute respiratory syndrome virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24319085" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Severe acute respiratory syndrome beyond Amoy Gardens: completing the incomplete legacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21737332" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Super-spreaders in infectious diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15158632" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12781535" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28727803" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Role of fomites in SARS transmission during the largest hospital outbreak in Hong Kong.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29244221" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Routes of transmission of influenza A H1N1, SARS CoV, and norovirus in air cabin: Comparative analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16292310" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Superspreading and the effect of individual variation on disease emergence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12958366" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26133021" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Brief Report: Incubation Period Duration and Severity of Clinical Disease Following Severe Acute Respiratory Syndrome Coronavirus Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12734147" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14597455" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12748632" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Aetiology: Koch's postulates fulfilled for SARS virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12730500" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Characterization of a novel coronavirus associated with severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12781537" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12730501" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The Genome sequence of the SARS-associated coronavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12730501" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The Genome sequence of the SARS-associated coronavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12845623" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The clinical pathology of severe acute respiratory syndrome (SARS): a report from China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20610717" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30301856" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18478121" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : IL-12 RB1 genetic variants contribute to human susceptibility to severe acute respiratory syndrome infection among Chinese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15838797" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15496474" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14647384" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16007097" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21068237" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16339146" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12680522" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Preliminary clinical description of severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15843851" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Severe acute respiratory syndrome epidemic in Taiwan, 2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12885985" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12781012" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12682352" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A major outbreak of severe acute respiratory syndrome in Hong Kong.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14684510" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Chest radiographic manifestations of severe acute respiratory syndrome in health care workers: the Toronto experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12818821" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Severe acute respiratory syndrome: radiographic and CT findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12759474" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14684509" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : High-resolution CT findings of severe acute respiratory syndrome at presentation and after admission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27501327" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Thin-Section Computed Tomography Manifestations During Convalescence and Long-Term Follow-Up of Patients with Severe Acute Respiratory Syndrome (SARS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15295381" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15270922" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12781536" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Lung pathology of fatal severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28466096" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15031782" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Serology of severe acute respiratory syndrome: implications for surveillance and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16275947" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18382647" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14707219" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15522678" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The aetiology, origins, and diagnosis of severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14633867" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14522060" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Early diagnosis of SARS coronavirus infection by real time RT-PCR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15498155" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Viral loads in clinical specimens and SARS manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16968120" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : SARS: systematic review of treatment effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16002945" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19508438" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Avascular osteonecrosis after treatment of SARS: a 3-year longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15766649" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Treatment and vaccines for severe acute respiratory syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28659436" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14693874" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing, 2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15175437" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33162020" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Responding to the Severe Acute Respiratory Syndrome (SARS) Outbreak: Lessons Learned in a Toronto Emergency Department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29140516" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Effectiveness of Masks and Respirators Against Respiratory Infections in Healthcare Workers: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17416434" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20831383" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15448374" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15210961" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19683779" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20374001" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16621188" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15220033" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18941225" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30830861" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14983044" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18986662" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16796401" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
